Eli Lilly to Acquire Ajax Therapeutics for Up to $2.3B
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy LLY?
Source: seekingalpha
- Acquisition Value: Eli Lilly has agreed to acquire Ajax Therapeutics for up to $2.3 billion in cash, which includes an upfront payment and additional payments contingent on achieving specific clinical and regulatory milestones, significantly enhancing Lilly's market position in blood cancers.
- Clinical Development Potential: Ajax is developing next-generation therapies for blood cancers, particularly the AJ1-11095, a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept data expected in 2026, potentially transforming the treatment landscape.
- Efficacy Expectations: AJ1-11095 is anticipated to provide deeper and more durable disease control compared to existing therapies for myelofibrosis and polycythemia vera, offering patients longer treatment options and improving their quality of life.
- Strategic Investment Confidence: As a founding strategic investor in Ajax, Lilly expresses strong confidence in the development of AJ1-11095, believing its efficacy and tolerability advantages will allow for broad applications in both first- and second-line settings, further solidifying Lilly's leadership in oncology.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 917.650
Low
950.00
Averages
1192
High
1500
Current: 917.650
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly Acquires Ajax Therapeutics for $2.3 Billion
- Acquisition Details: Eli Lilly announced a deal to acquire Ajax Therapeutics and its lead asset AJ1-11095, a once-daily oral JAK2 inhibitor for myelofibrosis, for up to $2.3 billion, including upfront and milestone-based payments.
- Strategic Investment Background: As a founding strategic investor in Ajax, Lilly has long believed in its approach and is excited about AJ1-11095's potential to deliver superior efficacy and tolerability, allowing patients to remain on therapy longer.
- Market Reaction: Eli Lilly's stock traded at $884.65, up 0.05% in pre-market hours on the NYSE, indicating a positive market response to the acquisition, reflecting investor optimism about the new drug's potential.
- Future Outlook: This acquisition not only strengthens Lilly's oncology portfolio but also has the potential to enhance its market share in treating myelofibrosis patients through the clinical success of AJ1-11095, further solidifying its industry leadership.
See More
Eli Lilly to Acquire Ajax Therapeutics for Up to $2.3 Billion
- Acquisition Amount: Eli Lilly announced it will acquire privately-held Ajax Therapeutics for up to $2.3 billion in cash, demonstrating its intent to expand in the blood cancer treatment sector while potentially enhancing its product portfolio diversity.
- Market Impact: This acquisition is expected to strengthen Eli Lilly's competitiveness in the blood cancer treatment market, particularly in new drug development and marketing, further solidifying its leadership position in the biopharmaceutical industry.
- Strategic Significance: By integrating Ajax's technology and R&D capabilities, Eli Lilly can accelerate the market entry of innovative drugs, thereby meeting the growing patient demand and enhancing the company's long-term profitability.
- Investor Confidence: The announcement of this transaction may bolster investor confidence in Eli Lilly's future growth potential, especially regarding market share expansion and new product development in the blood cancer treatment sector.
See More
Eli Lilly to Acquire Ajax Therapeutics for Up to $2.3B
- Acquisition Value: Eli Lilly has agreed to acquire Ajax Therapeutics for up to $2.3 billion in cash, which includes an upfront payment and additional payments contingent on achieving specific clinical and regulatory milestones, significantly enhancing Lilly's market position in blood cancers.
- Clinical Development Potential: Ajax is developing next-generation therapies for blood cancers, particularly the AJ1-11095, a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept data expected in 2026, potentially transforming the treatment landscape.
- Efficacy Expectations: AJ1-11095 is anticipated to provide deeper and more durable disease control compared to existing therapies for myelofibrosis and polycythemia vera, offering patients longer treatment options and improving their quality of life.
- Strategic Investment Confidence: As a founding strategic investor in Ajax, Lilly expresses strong confidence in the development of AJ1-11095, believing its efficacy and tolerability advantages will allow for broad applications in both first- and second-line settings, further solidifying Lilly's leadership in oncology.
See More
Bristol Myers Squibb's Valuation Attractiveness Analysis
- Valuation Metrics Appeal: Bristol Myers Squibb (BMS) has a market cap of approximately $120 billion and a low forward P/E ratio of 9.4, significantly below the healthcare sector average of 17.3, indicating its attractiveness as a value investment, particularly for income-focused investors.
- Growth Prospects Challenges: While BMS's growth portfolio achieved a 17% sales increase in 2025, the expiration of patents for its top drugs, Eliquis and Opdivo, in 2028 is expected to significantly pressure future revenues, leading investors to adopt a cautious outlook on its growth potential.
- Dividend Appeal: With a forward dividend yield of 4.3% and a record of increasing dividends for 17 consecutive years, BMS remains attractive to income investors despite a lack of significant growth, helping to maintain investor confidence in the stock.
- Market Competition Analysis: Although BMS's valuation metrics are relatively low, Pfizer's forward P/E ratio stands at 9.1, indicating that there are other more attractive investment options in the market, and BMS needs to identify its unique value proposition to attract more investors.
See More
SpaceX Plans IPO with $1.75 Trillion Valuation
- Market Valuation Analysis: SpaceX plans to go public with a valuation of $1.75 trillion, a figure that not only surpasses Tesla's market cap but also exceeds that of Walmart and Berkshire Hathaway, indicating strong market expectations for its future growth.
- Revenue and Valuation Ratio: Although SpaceX generated approximately $18.5 billion in revenue last year, leading to a price-to-sales ratio near 95, its potential Starlink business is projected to achieve $60 billion in annual revenue in the coming years, potentially lowering its P/S ratio to 29 and reflecting market recognition of its growth potential.
- Starlink User Growth: Starlink currently boasts over 10 million users globally, with projections of reaching 30 to 50 million users; if averaged at $100 per month, this could significantly boost Starlink's revenue, further supporting SpaceX's high valuation.
- Future Market Potential: SpaceX's Starship could unlock new markets such as asteroid mining, lunar bases, and space tourism, and if successful, could greatly enhance its market position, making the $1.75 trillion valuation seem like just the beginning.
See More
Valuation Analysis of Bristol Myers Squibb Stock
- Valuation Appeal: Bristol Myers Squibb (BMS) has a forward P/E ratio of 9.4, significantly lower than the healthcare sector average of 17.3, indicating its stock may attract value investors, especially with a market cap of around $120 billion.
- Growth Prospects Challenges: Despite BMS's appealing growth potential, the looming patent cliff poses a significant risk for revenue decline in the coming years, particularly as its top drugs, Eliquis and Opdivo, face patent expiration in 2028, which could severely impact total revenue.
- Dividend Attraction: With a forward dividend yield of 4.3% and a record of increasing dividends for 17 consecutive years, BMS remains attractive to income investors, who may prioritize steady cash flow over growth concerns.
- Competitor Comparison: Compared to competitors like Pfizer (PFE) and AbbVie, BMS's lower valuation may not be enough to offset the competitive pressure, as AbbVie appears more attractively valued when considering growth projections over the next five years.
See More
Eli Lilly Acquires Ajax Therapeutics for $2.3 Billion
- Acquisition Details: Eli Lilly announced a deal to acquire Ajax Therapeutics and its lead asset AJ1-11095, a once-daily oral JAK2 inhibitor for myelofibrosis, for up to $2.3 billion, including upfront and milestone-based payments.
- Strategic Investment Background: As a founding strategic investor in Ajax, Lilly has long believed in its approach and is excited about AJ1-11095's potential to deliver superior efficacy and tolerability, allowing patients to remain on therapy longer.
- Market Reaction: Eli Lilly's stock traded at $884.65, up 0.05% in pre-market hours on the NYSE, indicating a positive market response to the acquisition, reflecting investor optimism about the new drug's potential.
- Future Outlook: This acquisition not only strengthens Lilly's oncology portfolio but also has the potential to enhance its market share in treating myelofibrosis patients through the clinical success of AJ1-11095, further solidifying its industry leadership.
See More
Eli Lilly to Acquire Ajax Therapeutics for Up to $2.3 Billion
- Acquisition Amount: Eli Lilly announced it will acquire privately-held Ajax Therapeutics for up to $2.3 billion in cash, demonstrating its intent to expand in the blood cancer treatment sector while potentially enhancing its product portfolio diversity.
- Market Impact: This acquisition is expected to strengthen Eli Lilly's competitiveness in the blood cancer treatment market, particularly in new drug development and marketing, further solidifying its leadership position in the biopharmaceutical industry.
- Strategic Significance: By integrating Ajax's technology and R&D capabilities, Eli Lilly can accelerate the market entry of innovative drugs, thereby meeting the growing patient demand and enhancing the company's long-term profitability.
- Investor Confidence: The announcement of this transaction may bolster investor confidence in Eli Lilly's future growth potential, especially regarding market share expansion and new product development in the blood cancer treatment sector.
See More
Eli Lilly to Acquire Ajax Therapeutics for Up to $2.3B
- Acquisition Value: Eli Lilly has agreed to acquire Ajax Therapeutics for up to $2.3 billion in cash, which includes an upfront payment and additional payments contingent on achieving specific clinical and regulatory milestones, significantly enhancing Lilly's market position in blood cancers.
- Clinical Development Potential: Ajax is developing next-generation therapies for blood cancers, particularly the AJ1-11095, a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept data expected in 2026, potentially transforming the treatment landscape.
- Efficacy Expectations: AJ1-11095 is anticipated to provide deeper and more durable disease control compared to existing therapies for myelofibrosis and polycythemia vera, offering patients longer treatment options and improving their quality of life.
- Strategic Investment Confidence: As a founding strategic investor in Ajax, Lilly expresses strong confidence in the development of AJ1-11095, believing its efficacy and tolerability advantages will allow for broad applications in both first- and second-line settings, further solidifying Lilly's leadership in oncology.
See More
Bristol Myers Squibb's Valuation Attractiveness Analysis
- Valuation Metrics Appeal: Bristol Myers Squibb (BMS) has a market cap of approximately $120 billion and a low forward P/E ratio of 9.4, significantly below the healthcare sector average of 17.3, indicating its attractiveness as a value investment, particularly for income-focused investors.
- Growth Prospects Challenges: While BMS's growth portfolio achieved a 17% sales increase in 2025, the expiration of patents for its top drugs, Eliquis and Opdivo, in 2028 is expected to significantly pressure future revenues, leading investors to adopt a cautious outlook on its growth potential.
- Dividend Appeal: With a forward dividend yield of 4.3% and a record of increasing dividends for 17 consecutive years, BMS remains attractive to income investors despite a lack of significant growth, helping to maintain investor confidence in the stock.
- Market Competition Analysis: Although BMS's valuation metrics are relatively low, Pfizer's forward P/E ratio stands at 9.1, indicating that there are other more attractive investment options in the market, and BMS needs to identify its unique value proposition to attract more investors.
See More
SpaceX Plans IPO with $1.75 Trillion Valuation
- Market Valuation Analysis: SpaceX plans to go public with a valuation of $1.75 trillion, a figure that not only surpasses Tesla's market cap but also exceeds that of Walmart and Berkshire Hathaway, indicating strong market expectations for its future growth.
- Revenue and Valuation Ratio: Although SpaceX generated approximately $18.5 billion in revenue last year, leading to a price-to-sales ratio near 95, its potential Starlink business is projected to achieve $60 billion in annual revenue in the coming years, potentially lowering its P/S ratio to 29 and reflecting market recognition of its growth potential.
- Starlink User Growth: Starlink currently boasts over 10 million users globally, with projections of reaching 30 to 50 million users; if averaged at $100 per month, this could significantly boost Starlink's revenue, further supporting SpaceX's high valuation.
- Future Market Potential: SpaceX's Starship could unlock new markets such as asteroid mining, lunar bases, and space tourism, and if successful, could greatly enhance its market position, making the $1.75 trillion valuation seem like just the beginning.
See More
Valuation Analysis of Bristol Myers Squibb Stock
- Valuation Appeal: Bristol Myers Squibb (BMS) has a forward P/E ratio of 9.4, significantly lower than the healthcare sector average of 17.3, indicating its stock may attract value investors, especially with a market cap of around $120 billion.
- Growth Prospects Challenges: Despite BMS's appealing growth potential, the looming patent cliff poses a significant risk for revenue decline in the coming years, particularly as its top drugs, Eliquis and Opdivo, face patent expiration in 2028, which could severely impact total revenue.
- Dividend Attraction: With a forward dividend yield of 4.3% and a record of increasing dividends for 17 consecutive years, BMS remains attractive to income investors, who may prioritize steady cash flow over growth concerns.
- Competitor Comparison: Compared to competitors like Pfizer (PFE) and AbbVie, BMS's lower valuation may not be enough to offset the competitive pressure, as AbbVie appears more attractively valued when considering growth projections over the next five years.
See More
